OncoSec Medical Incorporated (ONCS) Stock Analysis

OncoSec Medical Incorporated (ONCS) Healthcare & Pipeline Overview

OncoSec Medical Incorporated is a late-stage biotechnology company specializing in immuno-oncology with a focus on intra-tumoral DNA-based therapeutics. Their lead product, ImmunoPulse IL-12, leverages electroporation to deliver DNA-encoded interleukin-12, aiming to reverse immunosuppression within tumors and enhance anti-tumor immune responses, positioning them in the competitive cancer treatment landscape.

What Is the Investment Thesis for ONCS?

OncoSec Medical Incorporated presents a focused investment opportunity within the immuno-oncology space, primarily driven by the potential of its ImmunoPulse IL-12 technology. The ongoing clinical trials, particularly the collaborations with Merck (KEYNOTE-695 and KEYNOTE-890), represent significant catalysts for potential value creation. Success in these trials could lead to regulatory approvals and subsequent commercialization, driving revenue growth. The company's focus on reversing the immunosuppressive tumor microenvironment addresses a critical challenge in cancer immunotherapy. However, the company's lack of revenue, dependence on clinical trial outcomes, and competition within the biotechnology sector pose substantial risks. The company's market capitalization is $0.00B as of 2026-03-18. Positive clinical data and strategic partnerships are key to unlocking value.

Based on FMP financials and quantitative analysis

ONCS Key Highlights

OncoSec's lead product candidate is ImmunoPulse IL-12, an intra-tumoral DNA-based therapeutic.

• The company is collaborating with Merck & Co., Inc. on KEYNOTE-695 and KEYNOTE-890 studies.
• OncoSec is focused on reversing the immunosuppressive microenvironment in tumors.
• The company has research collaborations with Duke University and Roswell Park Comprehensive Cancer Center.
• OncoSec's market capitalization is $0.00B as of 2026-03-18.

Who Are ONCS's Competitors?

ONCS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ONCS's Key Strengths?

Proprietary ImmunoPulse IL-12 technology.

• Clinical trial collaborations with Merck & Co., Inc.
• Focus on reversing the immunosuppressive tumor microenvironment.
• Research collaborations with Duke University and Roswell Park Comprehensive Cancer Center.

What Are ONCS's Weaknesses?

Lack of revenue and dependence on clinical trial outcomes.

• Competition within the biotechnology sector.
• Limited financial resources.
• Reliance on key personnel and partnerships.

What Could Drive ONCS Stock Higher?

ONCS catalyst: Data readouts from ongoing clinical trials of ImmunoPulse IL-12 in combination with KEYTRUDA (KEYNOTE-695 and KEYNOTE-890).

• Potential regulatory submissions and approvals for ImmunoPulse IL-12 in advanced melanoma and metastatic triple-negative breast cancer.
• Expansion of clinical trials to new cancer indications.
• Strategic partnerships and collaborations with other pharmaceutical companies.

What Are the Key Risks for ONCS?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Failure to achieve positive clinical trial results.
• Regulatory hurdles and delays in obtaining approvals.
• Competition from other immuno-oncology therapies.
• Patent expiration and loss of exclusivity.
• Dependence on key personnel and partnerships.

What Are the Growth Opportunities for ONCS?

• Expansion of ImmunoPulse IL-12 into New Cancer Indications: OncoSec has the opportunity to expand the application of ImmunoPulse IL-12 beyond melanoma and triple-negative breast cancer to other cancer types, such as liver, lung, bladder, and pancreatic cancers. This expansion could significantly increase the addressable market for the therapy. The timeline for this growth opportunity depends on the successful completion of preclinical and clinical studies in these new indications, potentially leading to new clinical trials within the next 2-3 years. The market for cancer therapies is estimated to reach $200 billion by 2028.
• Strategic Partnerships and Collaborations: OncoSec can leverage strategic partnerships and collaborations with other pharmaceutical companies and research institutions to accelerate the development and commercialization of its ImmunoPulse IL-12 technology. These partnerships can provide access to additional funding, expertise, and resources. The company already has collaborations with Merck, Duke University and Roswell Park Comprehensive Cancer Center. Expanding these collaborations or forming new ones could lead to faster clinical trial enrollment and regulatory approvals, potentially within the next 1-2 years.
• Advancements in Electroporation Technology: OncoSec can further enhance the efficacy of its ImmunoPulse IL-12 therapy by investing in advancements in electroporation technology. This could involve developing more efficient and targeted delivery methods to ensure that the DNA-encoded interleukin-12 reaches the tumor cells effectively. Improved electroporation technology could lead to increased anti-tumor immune responses and improved patient outcomes. The timeline for this growth opportunity depends on the pace of technological innovation and the availability of funding for research and development, potentially leading to significant improvements within the next 3-5 years.
• Development of Combination Therapies: OncoSec can explore the potential of combining ImmunoPulse IL-12 with other cancer therapies, such as chemotherapy, radiation therapy, and other immunotherapies. This could lead to synergistic effects and improved patient outcomes. The company is already exploring combination therapies with KEYTRUDA. Expanding these efforts to include other therapies could broaden the applicability of ImmunoPulse IL-12 and increase its market potential. The timeline for this growth opportunity depends on the results of preclinical and clinical studies evaluating these combination therapies, potentially leading to new clinical trials within the next 2-3 years.
• Out-licensing or Acquisition of ImmunoPulse IL-12 Technology: OncoSec could pursue an out-licensing or acquisition strategy, partnering with a larger pharmaceutical company to further develop and commercialize its ImmunoPulse IL-12 technology. This could provide OncoSec with a significant upfront payment, milestone payments, and royalties on future sales. An out-licensing or acquisition deal could accelerate the development and commercialization of ImmunoPulse IL-12 and provide OncoSec with the financial resources to pursue other research and development initiatives. The timing of this growth opportunity is uncertain and depends on market conditions and the interest of potential partners.

What Are ONCS's Competitive Advantages?

• Proprietary ImmunoPulse IL-12 technology.
• Patent protection for its DNA-based therapeutics and electroporation delivery system.
• Clinical trial data demonstrating the efficacy of ImmunoPulse IL-12.
• Collaborations with leading pharmaceutical companies and research institutions.

What Does ONCS Do?

OncoSec Medical Incorporated, founded in 2008 and headquartered in Pennington, New Jersey, is a biotechnology company focused on the development and commercialization of innovative immuno-oncology therapies. Originally named NetVentory Solutions Inc., the company rebranded to OncoSec Medical Incorporated in March 2011 to reflect its strategic shift towards cancer therapeutics. The company's core technology revolves around intra-tumoral DNA-based therapeutics designed to stimulate and augment anti-tumor immune responses. Their lead product candidate, ImmunoPulse IL-12, utilizes an electroporation device to deliver a DNA-encoded interleukin-12 directly into the tumor, aiming to reverse the immunosuppressive microenvironment and promote a robust anti-cancer immune response. OncoSec is actively engaged in clinical trials to evaluate the efficacy of ImmunoPulse IL-12, both as a monotherapy and in combination with other cancer treatments. Key collaborations include partnerships with Merck & Co., Inc. to investigate ImmunoPulse IL-12 in conjunction with KEYTRUDA in advanced melanoma (KEYNOTE-695) and metastatic triple-negative breast cancer (KEYNOTE-890). Additionally, OncoSec has research collaborations with Duke University's Center for Applied Therapeutics and Roswell Park Comprehensive Cancer Center to explore novel therapeutic combinations and delivery methods. The company is also exploring the potential of its technology to treat various visceral lesions, including liver, lung, bladder, and pancreatic cancers.

What Products and Services Does ONCS Offer?

• Develop intra-tumoral DNA-based therapeutics.
• Design therapies to stimulate anti-tumor immune responses.
• Commercialize therapies for the treatment of cancer.
• Utilize electroporation to deliver DNA-encoded interleukin-12.
• Reverse the immunosuppressive microenvironment in tumors.
• Conduct clinical trials to evaluate the efficacy of ImmunoPulse IL-12.
• Collaborate with pharmaceutical companies and research institutions.

How Does ONCS Make Money?

• Develop and patent novel immuno-oncology therapies.
• Conduct clinical trials to demonstrate the safety and efficacy of their therapies.
• Seek regulatory approvals from agencies like the FDA.
• Potentially commercialize approved therapies directly or through partnerships.

What Industry Does ONCS Operate In?

OncoSec Medical Incorporated operates within the rapidly evolving immuno-oncology sector, a segment of the biotechnology industry focused on harnessing the body's immune system to fight cancer. The market is characterized by intense competition, with numerous companies developing novel immunotherapies, including checkpoint inhibitors, CAR-T cell therapies, and oncolytic viruses. OncoSec's approach of using intra-tumoral DNA-based therapeutics differentiates it from some competitors, but it also faces challenges in demonstrating superior efficacy and safety. The immuno-oncology market is projected to continue growing, driven by increasing cancer incidence and advancements in understanding the tumor microenvironment. OncoSec's success hinges on its ability to navigate this competitive landscape and secure regulatory approvals for its ImmunoPulse IL-12 technology.

Who Are ONCS's Key Customers?

• Patients with advanced melanoma.
• Patients with metastatic triple-negative breast cancer.
• Hospitals and cancer treatment centers.
• Pharmaceutical companies through collaborations and licensing agreements.

OncoSec Medical Incorporated's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

OncoSec Medical Incorporated (ONCS) Valuation Context

Valued at $1.65M, ONCS is classified as a micro-cap stock.

Company Profile

OncoSec Medical Incorporated operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Pennington, US. The company is led by CEO Robert H. Arch. ONCS has traded publicly since 2010.

ONCS Financials

ONCS Latest News

No recent news available for ONCS.

What Investors Ask About OncoSec Medical Incorporated (ONCS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources